Discover open access scientific publications

Search, annotate, share and cite publications

Publications by F.B. Hagemeister

Lenalidomide and Obinutuzumab With Chop for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Phase I/Ii Results

Hematological Oncology

English

Treatment With Combination of Lenalidomide and Rituximab Achieves Durable Responses in a Long Term Follow Up of Patients With Indolent Non-Hodgkin's Lymphoma

Hematological Oncology

English

Related publications

Decitabine Plus R-Chop in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma: Interim Results of a Phase I/Ii Study

Hematological Oncology

English

Rituximab, Lenalidomide, and Ibrutinib Alone and Combined With Chemotherapy for Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Hematological Oncology

English

Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone Prior to Combination With Chemotherapy for Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Hematological Oncology

English

Phase Ii Study of Durvalumab (Anti-Pd-L1) Combined With Either R-Chop or Lenalidomide and R-Chop in Previously Untreated, High-Risk Diffuse Large B-Cell Lymphoma

Hematological Oncology

English

Addition of Lenalidomide to R-Chop (R2chop) Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma (Dlbcl): First Report of Ecog-Acrin1412 a Randomized Phase 2 Us Intergroup Study of R2chop vs R-Chop

Hematological Oncology

English

Hypogammaglobulinemia and Hypocomplementemia as Strong Prognostic Factors in Newly Diagnosed Diffuse Large B Cell Lymphoma

Hematological Oncology

English

ROBUST: First Report of Phase III Randomized Study of Lenalidomide/R-Chop (R2 -CHOP) vs Placebo/R-Chop in Previously Untreated ABC-type Diffuse Large B-Cell Lymphoma

Hematological Oncology

English

Robust: Phase Iii Randomized Study of Lenalidomide/R-Chop vs Placebo/R-Chop in Untreated Abc-Type Diffuse Large B-Cell Lymphoma and Feasibility of Cell of Origin Subtyping

Hematological Oncology

English

A Phase Ii Study of Lenalidomide and Rituximab (R²) Combination in Patients With High-Risk Refractory/Relapsed Diffuse Large B-Cell Lymphoma

Hematological Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by F.B. Hagemeister

Lenalidomide and Obinutuzumab With Chop for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Phase I/Ii Results

Treatment With Combination of Lenalidomide and Rituximab Achieves Durable Responses in a Long Term Follow Up of Patients With Indolent Non-Hodgkin's Lymphoma

Related publications

Decitabine Plus R-Chop in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma: Interim Results of a Phase I/Ii Study

Rituximab, Lenalidomide, and Ibrutinib Alone and Combined With Chemotherapy for Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone Prior to Combination With Chemotherapy for Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Phase Ii Study of Durvalumab (Anti-Pd-L1) Combined With Either R-Chop or Lenalidomide and R-Chop in Previously Untreated, High-Risk Diffuse Large B-Cell Lymphoma

Addition of Lenalidomide to R-Chop (R2chop) Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma (Dlbcl): First Report of Ecog-Acrin1412 a Randomized Phase 2 Us Intergroup Study of R2chop vs R-Chop

Hypogammaglobulinemia and Hypocomplementemia as Strong Prognostic Factors in Newly Diagnosed Diffuse Large B Cell Lymphoma

ROBUST: First Report of Phase III Randomized Study of Lenalidomide/R-Chop (R2 -CHOP) vs Placebo/R-Chop in Previously Untreated ABC-type Diffuse Large B-Cell Lymphoma

Robust: Phase Iii Randomized Study of Lenalidomide/R-Chop vs Placebo/R-Chop in Untreated Abc-Type Diffuse Large B-Cell Lymphoma and Feasibility of Cell of Origin Subtyping

A Phase Ii Study of Lenalidomide and Rituximab (R²) Combination in Patients With High-Risk Refractory/Relapsed Diffuse Large B-Cell Lymphoma